At the 2017 annual meeting of the American Liver Disease Association, a large observational study reported that the use of direct antiviral (DAA) therapy to eradicate hepatitis C virus (HCV) can reduce the risk of liver cancer by 71%. In patients with cirrhosis and non-cirrhosis, the risk of liver cancer is reduced. In the United States, most primary liver cancer occurs in people infected with HCV. Researchers at the University of Washington hypothesized that the eradication of HCV could eliminate or at least significantly reduce the risk of kanser sa atay. However, before HCV eradication, the patient may have developed cirrhosis or liver fibrosis. Even if HCV eradication may be too late, there is still a risk of developing liver cancer. In addition, recent studies suggest that the risk of liver cancer in HCV-infected patients who have received new DAA treatment is still increased. The researchers analyzed 62,051 patients with HCV infection who received 83,695 antiviral treatments. After 180 days of antiviral treatment, an average of 3,271 new liver cancers occurred during a follow-up of 6.1 years. Patients with cirrhosis who failed treatment had the highest incidence of liver cancer (3.25 / 100 person-years), followed by patients with cirrhosis who had sustained virological response (SVR) (1.97 / 100 person-years), and patients who had no cirrhosis but failed treatment (0.87 / 100 person-years) and patients without cirrhosis who obtained SVR (0.24 / 100 person-years). Multivariate analysis showed that after adjusting for potential confounders, SVR was significantly associated with a lower risk of liver cancer, regardless of whether DAA treatment (aHR = 0.29), DAA combined with interferon treatment (aHR = 0.48), or interferon only treatment (aHR = 0.32).
Binibigyang-diin ng mga mananaliksik na ang isang pag-aaral sa European Liver Disease Congress noong nakaraang taon ay nagmungkahi na ang mga pasyente ng HCV na ginagamot sa DAA ay tila may mas mataas na rate ng pag-ulit ng kanser sa atay. Ang resultang ito ay napakakontrobersyal, dahil ang kaugnayan sa pagitan ng HCV at kanser sa atay ay nagmumungkahi na ang pagtanggal ng HCV ay dapat mabawasan Ang panganib ng kanser sa atay ay hindi upang mapataas ang panganib ng kanser sa atay. Ang pagtatapos ng obserbasyonal na pag-aaral na ito ay napakasigurado na ang pagtanggal ng DAA ng HCV ay maaaring mabawasan ang panganib ng kanser sa atay ng 71%, na nagmumungkahi na hindi kailangang mag-alala tungkol sa pagtanggal ng HCV upang mapataas ang panganib ng kanser sa atay. Ang pagtanggal ng HCV ay upang mabawasan ang panganib ng kanser sa atay.
